Clinical Pharmacology in HIV Therapy.
Anti-Retroviral Agents
Attention
Clinical
Comorbidity
HIV
HIV Infections
HIV-1
Health Services Accessibility
Morbidity
Pharmacology
antiretroviral therapy
drug interactions
drug nephrotoxicity
pharmacokinetics
Journal
Clinical journal of the American Society of Nephrology : CJASN
ISSN: 1555-905X
Titre abrégé: Clin J Am Soc Nephrol
Pays: United States
ID NLM: 101271570
Informations de publication
Date de publication:
07 03 2019
07 03 2019
Historique:
pubmed:
31
5
2018
medline:
1
4
2020
entrez:
31
5
2018
Statut:
ppublish
Résumé
The success of combination antiretroviral therapy in the treatment of HIV-1-positive individuals has shifted clinical attention toward combination antiretroviral drug regimens that optimize tolerability, long-term safety, and durable efficacy. Wherever patients have access to treatment, morbidity and mortality are increasingly driven by non-HIV-associated comorbidities, which may be observed earlier than in age-matched controls and despite the best available combination antiretroviral therapy. Similarly, HIV-1-positive individuals are now diagnosed and treated earlier with anticipated lifelong therapy. The contribution of specific antiretroviral agents to long-term morbidity and mortality is dependent on the pharmacologic characteristics of these agents, and it is increasingly important in this context.
Identifiants
pubmed: 29844056
pii: 01277230-201903000-00018
doi: 10.2215/CJN.02240218
pmc: PMC6419290
doi:
Substances chimiques
Anti-HIV Agents
0
Drug Combinations
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
435-444Subventions
Organisme : NIDA NIH HHS
ID : K24 DA035684
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI094189
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA026770
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK103574
Pays : United States
Organisme : NIDDK NIH HHS
ID : P01 DK056492
Pays : United States
Informations de copyright
Copyright © 2019 by the American Society of Nephrology.
Références
Atta MG, Deray G, Lucas GM: Antiretroviral nephrotoxicities. Semin Nephrol 28: 563–575, 2008
Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents: Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV, 2017. Available at: http://www.aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf . Accessed December 4, 2017
Günthard HF, Saag MS, Benson CA, del Rio C, Eron JJ, Gallant JE, Hoy JF, Mugavero MJ, Sax PE, Thompson MA, Gandhi RT, Landovitz RJ, Smith DM, Jacobsen DM, Volberding PA: Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 Recommendations of the International Antiviral Society-USA panel. JAMA 316: 191–210, 2016
Lucas GM, Ross MJ, Stock PG, Shlipak MG, Wyatt CM, Gupta SK, Atta MG, Wools-Kaloustian KK, Pham PA, Bruggeman LA, Lennox JL, Ray PE, Kalayjian RC; HIV Medicine Association of the Infectious Diseases Society of America: Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 Update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 59: e96–e138, 2014
Swanepoel CR, Atta MG, D’Agati VD, Estrella MM, Fogo AB, Naicker S, Post FA, Wearne N, Winkler CA, Cheung M, Wheeler DC, Winkelmayer WC, Wyatt CM; Conference Participants: Kidney disease in the setting of HIV infection: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 93: 545–559, 2018
Hara M, Suganuma A, Yanagisawa N, Imamura A, Hishima T, Ando M: Atazanavir nephrotoxicity. Clin Kidney J 8: 137–142, 2015
Waheed S, Attia D, Estrella MM, Zafar Y, Atta MG, Lucas GM, Fine DM: Proximal tubular dysfunction and kidney injury associated with tenofovir in HIV patients: A case series. Clin Kidney J 8: 420–425, 2015
Mocroft A, Kirk O, Reiss P, De Wit S, Sedlacek D, Beniowski M, Gatell J, Phillips AN, Ledergerber B, Lundgren JD; EuroSIDA Study Group: Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS 24: 1667–1678, 2010
Kopp JB, Miller KD, Mican JA, Feuerstein IM, Vaughan E, Baker C, Pannell LK, Falloon J: Crystalluria and urinary tract abnormalities associated with indinavir. Ann Intern Med 127: 119–125, 1997
Labarga P, Barreiro P, Martin-Carbonero L, Rodriguez-Novoa S, Solera C, Medrano J, Rivas P, Albalater M, Blanco F, Moreno V, Vispo E, Soriano V: Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. AIDS 23: 689–696, 2009
Calza L, Trapani F, Tedeschi S, Piergentili B, Manfredi R, Colangeli V, Viale P: Tenofovir-induced renal toxicity in 324 HIV-infected, antiretroviral-naïve patients. Scand J Infect Dis 43: 656–660, 2011
Hervey PS, Perry CM: Abacavir: A review of its clinical potential in patients with HIV infection. Drugs 60: 447–479, 2000
Martin MA, Kroetz DL: Abacavir pharmacogenetics--from initial reports to standard of care. Pharmacotherapy 33: 765–775, 2013
Charneira C, Godinho AL, Oliveira MC, Pereira SA, Monteiro EC, Marques MM, Antunes AM: Reactive aldehyde metabolites from the anti-HIV drug abacavir: Amino acid adducts as possible factors in abacavir toxicity. Chem Res Toxicol 24: 2129–2141, 2011
Clay PG: The abacavir hypersensitivity reaction: A review. Clin Ther 24: 1502–1514, 2002
Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C, Sayer D, Castley A, Mamotte C, Maxwell D, James I, Christiansen FT: Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 359: 727–732, 2002
Izzedine H, Launay-Vacher V, Aymard G, Legrand M, Deray G: Pharmacokinetics of abacavir in HIV-1-infected patients with impaired renal function. Nephron 89: 62–67, 2001
Moore KH, Barrett JE, Shaw S, Pakes GE, Churchus R, Kapoor A, Lloyd J, Barry MG, Back D: The pharmacokinetics of lamivudine phosphorylation in peripheral blood mononuclear cells from patients infected with HIV-1. AIDS 13: 2239–2250, 1999
Johnson MA, Verpooten GA, Daniel MJ, Plumb R, Moss J, Van Caesbroeck D, De Broe ME: Single dose pharmacokinetics of lamivudine in subjects with impaired renal function and the effect of haemodialysis. Br J Clin Pharmacol 46: 21–27, 1998
Heald AE, Hsyu PH, Yuen GJ, Robinson P, Mydlow P, Bartlett JA: Pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with renal dysfunction. Antimicrob Agents Chemother 40: 1514–1519, 1996
Valade E, Tréluyer JM, Bouazza N, Ghosn J, Foissac F, Benaboud S, Fauchet F, Viard JP, Urien S, Hirt D: Population pharmacokinetics of emtricitabine in HIV-1-infected adult patients. Antimicrob Agents Chemother 58: 2256–2261, 2014
Kearney BP, Flaherty JF, Shah J: Tenofovir disoproxil fumarate: Clinical pharmacology and pharmacokinetics. Clin Pharmacokinet 43: 595–612, 2004
Cihlar T, Ho ES, Lin DC, Mulato AS: Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs. Nucleosides Nucleotides Nucleic Acids 20: 641–648, 2001
Imaoka T, Kusuhara H, Adachi M, Schuetz JD, Takeuchi K, Sugiyama Y: Functional involvement of multidrug resistance-associated protein 4 (MRP4/ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir. Mol Pharmacol 71: 619–627, 2007
Libório AB, Andrade L, Pereira LV, Sanches TR, Shimizu MH, Seguro AC: Rosiglitazone reverses tenofovir-induced nephrotoxicity. Kidney Int 74: 910–918, 2008
Kohler JJ, Hosseini SH, Green E, Abuin A, Ludaway T, Russ R, Santoianni R, Lewis W: Tenofovir renal proximal tubular toxicity is regulated by OAT1 and MRP4 transporters. Lab Invest 91: 852–858, 2011
Herlitz LC, Mohan S, Stokes MB, Radhakrishnan J, D’Agati VD, Markowitz GS: Tenofovir nephrotoxicity: Acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities. Kidney Int 78: 1171–1177, 2010
Cez A, Brocheriou I, Lescure FX, Adam C, Girard PM, Pialoux G, Moestrup SK, Fellahi S, Bastard JP, Ronco P, Plaisier E: Decreased expression of megalin and cubilin and altered mitochondrial activity in tenofovir nephrotoxicity. Hum Pathol 73: 89–101, 2018
Novick TK, Choi MJ, Rosenberg AZ, McMahon BA, Fine D, Atta MG: Tenofovir alafenamide nephrotoxicity in an HIV-positive patient: A case report. Medicine (Baltimore) 96: e8046, 2017
Mitema D, Atta MG: The role of organic transporters in pharmacokinetics and nephrotoxicity of newer antiviral therapies for HIV and hepatitis C. Curr Drug Metab 16: 322–331, 2015
Slaven JE, Decker BS, Kashuba ADM, Atta MG, Wyatt CM, Gupta SK: Plasma and intracellular concentrations in HIV-infected patients requiring hemodialysis dosed with tenofovir disoproxil fumarate and emtricitabine. J Acquir Immune Defic Syndr 73: e8–e10, 2016
Birkus G, Kutty N, He GX, Mulato A, Lee W, McDermott M, Cihlar T: Activation of 9-[(R)-2-[[(S)-[[(S)-1-(Isopropoxycarbonyl)ethyl]amino] phenoxyphosphinyl]-methoxy]propyl]adenine (GS-7340) and other tenofovir phosphonoamidate prodrugs by human proteases. Mol Pharmacol 74: 92–100, 2008
Lee WA, He GX, Eisenberg E, Cihlar T, Swaminathan S, Mulato A, Cundy KC: Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue. Antimicrob Agents Chemother 49: 1898–1906, 2005
Ray AS, Cihlar T, Robinson KL, Tong L, Vela JE, Fuller MD, Wieman LM, Eisenberg EJ, Rhodes GR: Mechanism of active renal tubular efflux of tenofovir. Antimicrob Agents Chemother 50: 3297–3304, 2006
Bam RA, Yant SR, Cihlar T: Tenofovir alafenamide is not a substrate for renal organic anion transporters (OATs) and does not exhibit OAT-dependent cytotoxicity. Antivir Ther 19: 687–692, 2014
Ruane PJ, DeJesus E, Berger D, Markowitz M, Bredeek UF, Callebaut C, Zhong L, Ramanathan S, Rhee MS, Fordyce MW, Yale K: Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults. J Acquir Immune Defic Syndr 63: 449–455, 2013
Sax PE, Wohl D, Yin MT, Post F, DeJesus E, Saag M, Pozniak A, Thompson M, Podzamczer D, Molina JM, Oka S, Koenig E, Trottier B, Andrade-Villanueva J, Crofoot G, Custodio JM, Plummer A, Zhong L, Cao H, Martin H, Callebaut C, Cheng AK, Fordyce MW, McCallister S; GS-US-292-0104/0111 Study Team: Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: Two randomised, double-blind, phase 3, non-inferiority trials. Lancet 385: 2606–2615, 2015
Pozniak A, Arribas JR, Gathe J, Gupta SK, Post FA, Bloch M, Avihingsanon A, Crofoot G, Benson P, Lichtenstein K, Ramgopal M, Chetchotisakd P, Custodio JM, Abram ME, Wei X, Cheng A, McCallister S, SenGupta D, Fordyce MW; GS-US-292-0112 Study Team: Switching to tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected patients with renal impairment: 48-Week results from a single-arm, multicenter, open-label phase 3 study. J Acquir Immune Defic Syndr 71: 530–537, 2016
Gibson AK, Shah BM, Nambiar PH, Schafer JJ: Tenofovir alafenamide. Ann Pharmacother 50: 942–952, 2016
Lawson EB, Martin H, McCallister S, Shao Y, Vimal M, Kearney BP: Drug Interactions between Tenofovir Alafenamide and HIV Antiretroviral Agents. Presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, DC, September 5–9, 2014. Available at: http://www.natap.org/2014/ICAAC/ICAAC_23.htm . Accessed December 6, 2017
Adams JL, Greener BN, Kashuba AD: Pharmacology of HIV integrase inhibitors. Curr Opin HIV AIDS 7: 390–400, 2012
Cattaneo D, Gervasoni C, Meraviglia P, Landonio S, Fucile S, Cozzi V, Baldelli S, Pellegrini M, Galli M, Clementi E: Inter- and intra-patient variability of raltegravir pharmacokinetics in HIV-1-infected subjects. J Antimicrob Chemother 67: 460–464, 2012
Eron JJ Jr, Rockstroh JK, Reynes J, Andrade-Villanueva J, Ramalho-Madruga JV, Bekker LG, Young B, Katlama C, Gatell-Artigas JM, Arribas JR, Nelson M, Campbell H, Zhao J, Rodgers AJ, Rizk ML, Wenning L, Miller MD, Hazuda D, DiNubile MJ, Leavitt R, Isaacs R, Robertson MN, Sklar P, Nguyen BY; QDMRK Investigators: Raltegravir once daily or twice daily in previously untreated patients with HIV-1: A randomised, active-controlled, phase 3 non-inferiority trial. Lancet Infect Dis 11: 907–915, 2011
Kassahun K, McIntosh I, Cui D, Hreniuk D, Merschman S, Lasseter K, Azrolan N, Iwamoto M, Wagner JA, Wenning LA: Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Metab Dispos 35: 1657–1663, 2007
Min S, Song I, Borland J, Chen S, Lou Y, Fujiwara T, Piscitelli SC: Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. Antimicrob Agents Chemother 54: 254–258, 2010
Min S, Sloan L, DeJesus E, Hawkins T, McCurdy L, Song I, Stroder R, Chen S, Underwood M, Fujiwara T, Piscitelli S, Lalezari J: Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults. AIDS 25: 1737–1745, 2011
Cottrell ML, Hadzic T, Kashuba AD: Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir. Clin Pharmacokinet 52: 981–994, 2013
Reese MJ, Savina PM, Generaux GT, Tracey H, Humphreys JE, Kanaoka E, Webster LO, Harmon KA, Clarke JD, Polli JW: In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor. Drug Metab Dispos 41: 353–361, 2013
Koteff J, Borland J, Chen S, Song I, Peppercorn A, Koshiba T, Cannon C, Muster H, Piscitelli SC: A phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and para-aminohippurate clearance in healthy subjects. Br J Clin Pharmacol 75: 990–996, 2013
Weller S, Borland J, Chen S, Johnson M, Savina P, Wynne B, Wajima T, Peppercorn AF, Piscitelli SC: Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment. Eur J Clin Pharmacol 70: 29–35, 2014
Bollen PD, Rijnders BJ, Teulen MJ, Burger DM: Dolutegravir is not removed during hemodialysis. AIDS 30: 1490–1491, 2016
Mocroft A, Kirk O, Reiss P, De Wit S, Sedlacek D, Beniowski M, Gatell J, Phillips AN, Ledergerber B, Lundgren JD; EuroSIDA Study Group: Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS 24: 1667–1678, 2010
Kanzaki G, Tsuboi N, Miyazaki Y, Yokoo T, Utsunomiya Y, Hosoya T: Diffuse tubulointerstitial nephritis accompanied by renal crystal formation in an HIV-infected patient undergoing highly active antiretroviral therapy. Intern Med 51: 1543–1548, 2012
Izzedine H, M’rad MB, Bardier A, Daudon M, Salmon D: Atazanavir crystal nephropathy. AIDS 21: 2357–2358, 2007
Viglietti D, Verine J, De Castro N, Scemla A, Daudon M, Glotz D, Pillebout E: Chronic interstitial nephritis in an HIV type-1-infected patient receiving ritonavir-boosted atazanavir. Antivir Ther 16: 119–121, 2011
Jotwani V, Atta MG, Estrella MM: Kidney disease in HIV: Moving beyond HIV-associated nephropathy. J Am Soc Nephrol 28: 3142–3154, 2017
Xu L, Liu H, Murray BP, Callebaut C, Lee MS, Hong A, Strickley RG, Tsai LK, Stray KM, Wang Y, Rhodes GR, Desai MC: Cobicistat (GS-9350): A potent and selective inhibitor of human CYP3A as a novel pharmacoenhancer. ACS Med Chem Lett 1: 209–213, 2010
Mathias AA, German P, Murray BP, Wei L, Jain A, West S, Warren D, Hui J, Kearney BP: Pharmacokinetics and pharmacodynamics of GS-9350: A novel pharmacokinetic enhancer without anti-HIV activity. Clin Pharmacol Ther 87: 322–329, 2010
Lepist EI, Phan TK, Roy A, Tong L, Maclennan K, Murray B, Ray AS: Cobicistat boosts the intestinal absorption of transport substrates, including HIV protease inhibitors and GS-7340, in vitro. Antimicrob Agents Chemother 56: 5409–5413, 2012
Marzolini C, Gibbons S, Khoo S, Back D: Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications. J Antimicrob Chemother 71: 1755–1758, 2016
Sherman EM, Worley MV, Unger NR, Gauthier TP, Schafer JJ: Cobicistat: Review of a pharmacokinetic enhancer for HIV infection. Clin Ther 37: 1876–1893, 2015
Margolis AM, Heverling H, Pham PA, Stolbach A: A review of the toxicity of HIV medications. J Med Toxicol 10: 26–39, 2014
Flexner C: HIV-protease inhibitors. N Engl J Med 338: 1281–1292, 1998